Ben Goodger - Aslan Pharmaceuticals General Counsel
| ASLNDelisted Stock | USD 0.60 0.03 4.76% |
Executive
Ben Goodger is General Counsel of Aslan Pharmaceuticals
| Age | 61 |
| Phone | 65 6817 9598 |
| Web | https://aslanpharma.com |
Aslan Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5369) % which means that it has lost $0.5369 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.2664) %, meaning that it created substantial loss on money invested by shareholders. Aslan Pharmaceuticals' management efficiency ratios could be used to measure how well Aslan Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Aslan Pharmaceuticals currently holds 26.83 M in liabilities with Debt to Equity (D/E) ratio of 1.12, which is about average as compared to similar companies. Aslan Pharmaceuticals has a current ratio of 6.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Aslan Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Alice PharmD | Inventiva Sa | 53 | |
| Rose Weldon | Cullinan Oncology LLC | N/A | |
| Kristina Meyer | Inventiva Sa | N/A | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Tony Peng | Structure Therapeutics American | N/A | |
| James Burns | Agios Pharm | 46 | |
| Dr MBA | Acrivon Therapeutics, Common | N/A | |
| Xichen Lin | Structure Therapeutics American | 50 | |
| Jeffrey Fellows | Mineralys Therapeutics, Common | N/A | |
| Chau MBA | CytomX Therapeutics | N/A | |
| Ray Knox | Lyra Therapeutics | N/A | |
| Chandra MS | Erasca Inc | 53 | |
| YuWaye MD | CytomX Therapeutics | 56 | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Bruce Close | Acrivon Therapeutics, Common | N/A | |
| Lee Stern | Achilles Therapeutics PLC | N/A | |
| Minori MD | Compass Therapeutics | 61 | |
| Yingli Ma | Structure Therapeutics American | 50 | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Robert Shoemaker | Erasca Inc | 43 | |
Management Performance
| Return On Equity | -4.27 | |||
| Return On Asset | -0.54 |
Aslan Pharmaceuticals Leadership Team
Elected by the shareholders, the Aslan Pharmaceuticals' board of directors comprises two types of representatives: Aslan Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aslan. The board's role is to monitor Aslan Pharmaceuticals' management team and ensure that shareholders' interests are well served. Aslan Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aslan Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alexandre MD, Chief Officer | ||
| Stephen Doyle, Chief Officer | ||
| Charlie Hsu, Investor Director | ||
| ChiChin Wang, IR Director | ||
| Ben Goodger, General Counsel | ||
| Kiran Asarpota, Vice President-Finance | ||
| Carl EMBA, CEO Founder |
Aslan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aslan Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.27 | |||
| Return On Asset | -0.54 | |||
| Profit Margin | (2.92) % | |||
| Operating Margin | (2.91) % | |||
| Current Valuation | 288.33 M | |||
| Shares Outstanding | 2.83 M | |||
| Shares Owned By Insiders | 0.14 % | |||
| Shares Owned By Institutions | 13.21 % | |||
| Number Of Shares Shorted | 306.56 K | |||
| Price To Earning | (11.50) X |
Pair Trading with Aslan Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Aslan Stock
Moving against Aslan Stock
| 0.89 | WMT | Walmart Aggressive Push | PairCorr |
| 0.83 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
| 0.76 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.76 | JPM | JPMorgan Chase Fiscal Year End 10th of January 2025 | PairCorr |
| 0.75 | CSCO | Cisco Systems Aggressive Push | PairCorr |
The ability to find closely correlated positions to Aslan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aslan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aslan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aslan Pharmaceuticals to buy it.
The correlation of Aslan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aslan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aslan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |